Capital Impact Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Impact Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-5,195	Closed	-$723K	–	239
2016 Q1	$723K	Sell	5,195 -1,945	-27%	-$286K	0.35%	187
2015 Q4	$1.36M	Hold	7,140	–	–	0.65%	33
2015 Q3	$1.12M	Hold	7,140	–	–	0.57%	46
2015 Q2	$1.29M	Hold	7,140	–	–	0.59%	47
2015 Q1	$1.24M	Sell	7,140 -4,412	-38%	-$799K	0.57%	46
2014 Q4	$2.14M	Buy	11,552 +1,361	+13%	+$252K	1.01%	42
2014 Q3	$1.69M	Sell	10,191 -2,735	-21%	-$449K	2.23%	26
2014 Q2	$2.02M	Hold	12,926	–	–	1.52%	5
2014 Q1	$1.97M	Hold	12,926	–	–	1.59%	5
2013 Q4	$1.72M	Buy	+12,926	New	+$1.55M	1.38%	12

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital Impact Advisors's ALXN Position: Q2 2016 in Review

Capital Impact Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 5,195 shares — an estimated $723K sold.

Capital Impact Advisors first reported a position in ALXN in Q4 2013 and held it in 10 quarters. The position peaked at $2.14M in Q4 2014. 534 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

Capital Impact Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Capital Impact Advisors sold 5,195 Alexion Pharmaceuticals shares in Q2 2016, an estimated $723K.
Capital Impact Advisors first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Capital Impact Advisors's Alexion Pharmaceuticals position peaked at $2.14M in Q4 2014.
534 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Capital Impact Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.